A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs Navitoclax (Primary) ; Ruxolitinib
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 26 Nov 2019 Planned End Date changed from 26 Sep 2028 to 20 Sep 2028.
- 26 Nov 2019 Planned primary completion date changed from 20 Oct 2021 to 25 Mar 2020.
- 06 Nov 2019 Results (data cut off: 1 May 2019) evaluating the combination of navitoclax with ruxolitinib in pts with MFreleased at the 61st Annual Meeting and Exposition of the American Society of Hematology